EC Number   |
Title |
Organism |
|---|
   3.1.4.35 | Carboxyamidotriazole A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases |
Mus musculus |
| 3.1.4.35 | Carboxyamidotriazole A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases |
Rattus norvegicus |
| 3.1.4.35 | Identification of novel PDEdelta interacting proteins |
Homo sapiens |
| 3.1.4.35 | Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development |
Homo sapiens |
| 3.1.4.35 | 1-(2-(2,2,2-Trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors |
Homo sapiens |
| 3.1.4.35 | A novel role for a Drosophila homologue of cGMP-specific phosphodiesterase in the active transport of cGMP |
Drosophila sp. (in: flies) |
| 3.1.4.35 | A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia |
Homo sapiens |
| 3.1.4.35 | Activation of retinal rod cyclic GMP-phosphodiesterase by transducin: characterization of the complex formed by phosphodiesterase inhibitor and transducin alpha-subunit |
Bos taurus |
| 3.1.4.35 | Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition |
Homo sapiens |
| 3.1.4.35 | Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP |
Rattus norvegicus |
